Abstract:Background: Cryptococcus neoformans infections occur in immunocompromised patients, especially those with HIV infection, chemoradiotherapy after cancer, and organ transplantation. Infection can cause pneumonia and meningoencephalitis in severe cases with a high mortality rate if not treated. Although fluconazole and amphotericin B are the first-line treatments for cryptococcosis, the rate of fluconazole resistance has increased significantly due to long-term use. Minocycline is a derivative of tetracycline that exerts its antibacterial effect through inhibition of bacterial protein synthesis. It is also able to pass the blood-brain barrier to act on the central nervous system. The present study investigates the effects of minocycline in combination with antifungals in treating C. neoformans. Objective: To determine in vitro interactions of minocycline combined with itraconazole, voriconazole, posaconazole, fluconazole and amphotericin B against C. neoformans. Methods: The minimum inhibitory concentrations (MIC) of the antifungals were determined by the CLSI Clinical and Laboratory Standards Institute M27-A3 microdilution method. The in vitro synergistic effects of minocycline combined with itraconazole, voriconazole, posaconazole, fluconazole, and amphotericin B on C. neoformans were detected by the broth microdilution checkerboard technique and disk diffusion testing. Results and conclusion: The working concentration ranges were 0.125-4 µg/mL for itraconazole, 0.03-0.125 µg/ml for voriconazole, 0.03-1 µg/ml for posaconazole, 0.25-16 µg/ml for fluconazole, and 0.125-2 µg/ml for amphotericin B. The synergistic rates of minocycline combinations against C. neoformans were 55% with itraconazole, 10% with voriconazole, 85% with posaconazole, 20% with fluconazole, and 70% with amphotericin B. The effective MIC value of minocycline in the synergistic combination decreased to 2-32 µg/ml, while the MIC of itraconazole decreased to 0.03-0.125 µg/ml, voriconazole 0.03-0.125 µg/ml, posaconazole 0.03-0.125 µg/ml, 0.125-4 µg/ml fluconazole, and 0.06-0.50 µg/ml amphotericin B. The disk diffusion assay showed that the plates containing minocycline and antifungal drugs produced inhibition zones with diameters larger than the single drug plates. Minocycline showed no antagonistic effect in the combinations. In conclusion, the combination of minocycline and azoles or amphotericin B has synergistic effects against C. neoformans in vitro.

In Vitro Synergistic Effect of Tetrandrine on Ketoconazole Against Candida Parapsilosis Complex

In vitro interactions between tetrandrine and ketoconazole against Candida albicans determined by chequerboard method

Synergistic anti-candidal activity of tetrandrine on ketoconazole: an experimental study.

In Vitro Interactions of Micafungin with Amphotericin B, Itraconazole or Fluconazole Against the Pathogenic Phase of Penicillium Marneffei.

In Vitro Interaction of Itraconazole with Amphotericin B, Caspofungin, and Terbinafine Against Clinical Isolates of Trichosporon asahii

In Vitro Evaluation of the Activity of Tetrandrine Combined with Voriconazole Against Aspergillus Fumigatus by a Checkerboard Method

Synergistic Effects of Tetrandrine on the Antifungal Activity of Topical Ketoconazole Cream in the Treatment of Dermatophytoses: A Clinical Trial

The Efflux Pump Inhibitor Tetrandrine Exhibits Synergism with Fluconazole or Voriconazole Against Candida Parapsilosis

Synergistic Effects of Tetrandrine with Posaconazole Against Aspergillus Fumigatus.

In vitro interactions between tetrandrine and itraconazole against Aspergillus fumigatus determined by the checkerboard method

An in Vitro and in Vivo Study on the Synergistic Effect and Mechanism of Itraconazole or Voriconazole Alone and in Combination with Tetrandrine Against Aspergillus Fumigatus.

Synthesis and Synergistic Antifungal Effects of Monoketone Derivatives of Curcumin Against Fluconazole-Resistant Candida Spp.

Synergistic mechanism for tetrandrine on fluconazole against Candida albicans through the mitochondrial aerobic respiratory metabolism pathway.

In vitro synergistic effect of minocycline combined with antifungals against Cryptococcus neoformans

Synergistic Activity Of Econazole-Nitrate And Chelerythrine Against Clinical Isolates Of Candida Albicans

In vitro activity of terbinafine in combinations with other antifungi drugs against clinical pathogenic fungi of vulvovaginal candidiasis

Differential proteomic analysis of fluconazole-sensitive Candida albicans before and after tetrandrine treatment

In Vitro Interactions Between Tacrolimus and Azoles Against Candida Albicans Determined by Different Methods.

Detection of in vitro anti-fungal activity of 20 tetralin compounds

Mechanism of action of tetrandrine, a natural inhibitor of Candida albicans drug efflux pumps.

Tetrandrine Enhances the Antifungal Activity of Fluconazole in a Murine Model of Disseminated Candidiasis.